Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. - Madorsky Rowdo FP; Xiao G; Khramtsova GF; Nguyen J; Olopade OI; Martini R; Stonaker B; Boateng R; Oppong JK; Adjei EK; Awuah B; Kyei I; et al. (BioRxiv : the preprint server for biology, 2023)